+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 722 Actively Recruiting clinical trials

B

Actively Recruiting

Researchers at the Institute for Research on Viral and Hepatic Diseases are studying chronic liver diseases and tumors such as non-alcoholic steatohepatitis NASH, non-alcoholic fatty liver disease NAFLD, cirrhosis, and hepatocellular carcinoma HCC. These conditions can be linked to hepatitis viruses and lifestyle factors. There is currently no cure for NASH or cirrhosis, and treatment challenges arise from limited understanding of liver biology and disease complexity. The study aims to develop better preclinical models and identify new treatment targets using advanced techniques like single-cell RNA sequencing. The research involves establishing ex vivo models including spheroid cultures and mouse models from patient-derived liver tissues to study disease and test new therapies. Blood samples and biopsies taken during standard care procedures like surgery or diagnostic tests contribute to building these models and analyzing tumor and liver tissue at the cellular level. This approach helps profile tumor heterogeneity and discover biomarkers that may predict treatment response. Participants provide tissue and blood samples during routine care such as surgery, biopsies, or locoregional treatments. The study collects detailed data through advanced molecular profiling to understand liver disease progression and support personalized treatment strategies. The research team will monitor participants through their care period, which may average up to eight years, to evaluate liver-related outcomes and improve knowledge of chronic liver disease and liver cancer.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating the use of three-dimensional 3D modeling derived from pelvic MRI scans to better understand and manage deep endometriosis lesions. This retrospective study aims to determine if 3D reconstructions can improve surgical planning and support multidisciplinary care for patients with deep endometriosis. The study is conducted at a single center and focuses on the clinical relevance of this imaging technique. The study reviews medical data from patients with confirmed deep endometriosis who underwent surgical treatment at Strasbourg University Hospital between January 1, 2020, and December 31, 2022. It includes analyzing available and interpretable preoperative pelvic MRI scans to create 3D models of endometriosis lesions. These models are assessed for their impact on surgical planning and multidisciplinary management. Participants involvement includes retrospective review of their medical records, pelvic MRI scans, and surgical reports. Researchers compare standard surgical planning with planning aided by 3D modeling. The primary outcome measured is how 3D modeling influences surgical planning decisions. The study runs from October 27, 2025, to February 27, 2027, with primary outcome data collected up to December 27, 2026.

Age: 18Years +FEMALE
1 location
B

Actively Recruiting

Researchers aim to improve understanding and treatment of brain metastases from solid tumors, which currently have limited systemic treatment options. This study focuses on patients with newly diagnosed non-CNS metastatic solid tumors who are at high risk of developing central nervous system CNS metastases. By gathering detailed clinical and biological information, including analyses of circulating tumor DNA ctDNA from cerebrospinal fluid CSF samples, the study seeks to identify new therapeutic targets and develop innovative treatment strategies. The study is organized into three time periods before the first CNS event Part A, at the first CNS diagnosis Part B, and after the first CNS event Part C. Participants will undergo scheduled collections of plasma, serum, CSF samples, and non-CNS metastatic tumor tissue as applicable, along with brain MRI scans at specific intervals depending on their part in the study. Sample collections and imaging are scheduled annually, every few months, or as clinically indicated, aligned with the participants cancer type and study period. Participants will have regular assessments including imaging and biological sample collections to monitor disease progression and tumor biology. Researchers will analyze the epidemiology and biology of CNS metastases over approximately eight years. Study procedures include lumbar punctures for CSF collection, brain MRIs, and collection of tumor tissue when possible. Participants safety and life expectancy are considered, and follow-up will continue throughout the study duration to support data collection and understanding of CNS metastases.

Age: 18Years +All GendersPhase Not Applicable
17 locations
E

Actively Recruiting

Idiopathic hypersomnia IH is a chronic condition marked by excessive daytime sleepiness, long nighttime sleep, and difficulty waking up. It mostly affects young adults and can severely impact social, professional, and economic life. There are currently no approved treatments for IH symptoms, and this research aims to explore a treatment combining evening melatonin and morning bright light therapy, inspired by therapies for a related sleep disorder called delayed sleep-wake phase disorder. The study compares two groups over six weeks one receiving a combination of melatonin tablets in the evening plus active morning bright light therapy, and the other receiving placebo tablets and placebo light therapy. This randomized, triple-blind trial will evaluate the safety and potential benefits of this chronobiological treatment approach. Participants will be assessed at day 14 and day 45 using the Idiopathic Hypersomnia Severity Scale IHSS to measure symptoms. They will follow the treatment schedule carefully and be monitored throughout the study period. The trial includes adults aged 18 to 40 diagnosed with idiopathic hypersomnia, with stable medication use and ability to comply with therapy. Safety and symptom changes will be closely tracked during the 6-week treatment.

Age: 18Years - 40YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating GNT0004, a gene therapy using a recombinant adeno-associated viral vector designed to deliver a shortened but functional dystrophin gene to treat Duchenne muscular dystrophy DMD in boys. DMD is caused by mutations in the dystrophin gene, leading to muscle damage from lack of this key protein. This therapy aims to slow disease progression by producing dystrophin in heart and skeletal muscles. The study has three parts. Part 1 involved testing two doses of GNT0004 in five boys to determine the best dose with acceptable safety. Part 2 is a randomized, blinded phase lasting 18 months where participants receive either GNT0004 or a placebo after 18 months, those on placebo switch to GNT0004 and vice versa. Part 3 is a long-term follow-up lasting up to five years to monitor safety and treatment effects in all participants who received GNT0004. Participants undergo assessments including muscle biopsies, blood tests, MRI scans, and functional tests like the North Star Ambulatory Assessment, performed at various times throughout the study. Researchers monitor safety by tracking adverse events and immune responses. Long-term follow-up includes measuring muscle function and respiratory capacity over five years. The study involves ambulant boys aged 6 to 10 years with confirmed DMD who meet specific health criteria.

Age: 6Years - 10YearsMALEPhase 2Phase 3
14 locations
S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
P

Actively Recruiting

Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.

Age: 18Years +All GendersPhase Not Applicable
45 locations

1-10 of 722

1